86 related articles for article (PubMed ID: 17483951)
1. Functional study of the 830C>G polymorphism of the human carboxylesterase 2 gene.
Bellott R; Le Morvan V; Charasson V; Laurand A; Colotte M; Zanger UM; Klein K; Smith D; Bonnet J; Robert J
Cancer Chemother Pharmacol; 2008 Mar; 61(3):481-8. PubMed ID: 17483951
[TBL] [Abstract][Full Text] [Related]
2. Determination and analysis of single nucleotide polymorphisms and haplotype structure of the human carboxylesterase 2 gene.
Wu MH; Chen P; Wu X; Liu W; Strom S; Das S; Cook EH; Rosner GL; Dolan ME
Pharmacogenetics; 2004 Sep; 14(9):595-605. PubMed ID: 15475733
[TBL] [Abstract][Full Text] [Related]
3. Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan.
Xu G; Zhang W; Ma MK; McLeod HL
Clin Cancer Res; 2002 Aug; 8(8):2605-11. PubMed ID: 12171891
[TBL] [Abstract][Full Text] [Related]
4. Carboxylesterase isoform 2 mRNA expression in peripheral blood mononuclear cells is a predictive marker of the irinotecan to SN38 activation step in colorectal cancer patients.
Cecchin E; Corona G; Masier S; Biason P; Cattarossi G; Frustaci S; Buonadonna A; Colussi A; Toffoli G
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6901-7. PubMed ID: 16203781
[TBL] [Abstract][Full Text] [Related]
5. Expression and characterization of a human carboxylesterase 2 splice variant.
Schiel MA; Green SL; Davis WI; Sanghani PC; Bosron WF; Sanghani SP
J Pharmacol Exp Ther; 2007 Oct; 323(1):94-101. PubMed ID: 17636009
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenetics of human carboxylesterase 2, an enzyme involved in the activation of irinotecan into SN-38.
Charasson V; Bellott R; Meynard D; Longy M; Gorry P; Robert J
Clin Pharmacol Ther; 2004 Dec; 76(6):528-35. PubMed ID: 15592324
[TBL] [Abstract][Full Text] [Related]
7. Haplotypes and a novel defective allele of CES2 found in a Japanese population.
Kim SR; Sai K; Tanaka-Kagawa T; Jinno H; Ozawa S; Kaniwa N; Saito Y; Akasawa A; Matsumoto K; Saito H; Kamatani N; Shirao K; Yamamoto N; Yoshida T; Minami H; Ohtsu A; Saijo N; Sawada J
Drug Metab Dispos; 2007 Oct; 35(10):1865-72. PubMed ID: 17640957
[TBL] [Abstract][Full Text] [Related]
8. Carboxylesterase 2 as a Determinant of Response to Irinotecan and Neoadjuvant FOLFIRINOX Therapy in Pancreatic Ductal Adenocarcinoma.
Capello M; Lee M; Wang H; Babel I; Katz MH; Fleming JB; Maitra A; Wang H; Tian W; Taguchi A; Hanash SM
J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 26025324
[TBL] [Abstract][Full Text] [Related]
9. Determinants of the cytotoxicity of irinotecan in two human colorectal tumor cell lines.
Pavillard V; Agostini C; Richard S; Charasson V; Montaudon D; Robert J
Cancer Chemother Pharmacol; 2002 Apr; 49(4):329-35. PubMed ID: 11914913
[TBL] [Abstract][Full Text] [Related]
10. Regulation and expression of aberrant methylation on irinotecan metabolic genes CES2, UGT1A1 and GUSB in the in-vitro cultured colorectal cancer cells.
Xie FW; Peng YH; Chen X; Chen X; Li J; Yu ZY; Wang WW; Ouyang XN
Biomed Pharmacother; 2014 Feb; 68(1):31-7. PubMed ID: 24439671
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients.
Rouits E; Charasson V; Pétain A; Boisdron-Celle M; Delord JP; Fonck M; Laurand A; Poirier AL; Morel A; Chatelut E; Robert J; Gamelin E
Br J Cancer; 2008 Oct; 99(8):1239-45. PubMed ID: 18797458
[TBL] [Abstract][Full Text] [Related]
12. The Relationship between
Ishimine M; Lee HC; Nakaoka H; Orita H; Kobayashi T; Mizuguchi K; Endo M; Inoue I; Sato K; Yokomizo T
Dis Markers; 2018; 2018():5280736. PubMed ID: 29651325
[TBL] [Abstract][Full Text] [Related]
13. Association of carboxylesterase 1A genotypes with irinotecan pharmacokinetics in Japanese cancer patients.
Sai K; Saito Y; Tatewaki N; Hosokawa M; Kaniwa N; Nishimaki-Mogami T; Naito M; Sawada J; Shirao K; Hamaguchi T; Yamamoto N; Kunitoh H; Tamura T; Yamada Y; Ohe Y; Yoshida T; Minami H; Ohtsu A; Matsumura Y; Saijo N; Okuda H
Br J Clin Pharmacol; 2010 Aug; 70(2):222-33. PubMed ID: 20653675
[TBL] [Abstract][Full Text] [Related]
14. Clinical implications of CES2 RNA expression in neuroblastoma.
Uchida K; Otake K; Tanaka K; Hashimoto K; Saigusa S; Matsushita K; Koike Y; Inoue M; Ueeda M; Okugawa Y; Inoue Y; Mohri Y; Kusunoki M
J Pediatr Surg; 2013 Mar; 48(3):502-9. PubMed ID: 23480903
[TBL] [Abstract][Full Text] [Related]
15. Hydrolysis of irinotecan and its oxidative metabolites, 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino] carbonyloxycamptothecin and 7-ethyl-10-[4-(1-piperidino)-1-amino]-carbonyloxycamptothecin, by human carboxylesterases CES1A1, CES2, and a newly expressed carboxylesterase isoenzyme, CES3.
Sanghani SP; Quinney SK; Fredenburg TB; Davis WI; Murry DJ; Bosron WF
Drug Metab Dispos; 2004 May; 32(5):505-11. PubMed ID: 15100172
[TBL] [Abstract][Full Text] [Related]
16. Carboxylesterases expressed in human colon tumor tissue and their role in CPT-11 hydrolysis.
Sanghani SP; Quinney SK; Fredenburg TB; Sun Z; Davis WI; Murry DJ; Cummings OW; Seitz DE; Bosron WF
Clin Cancer Res; 2003 Oct; 9(13):4983-91. PubMed ID: 14581373
[TBL] [Abstract][Full Text] [Related]
17. Relationship between the expression of CES2, UGT1A1, and GUSB in colorectal cancer tissues and aberrant methylation.
Xie FW; Peng Y; Chen X; Chen X; Li J; Wang W; Yu Z; Ouyang X
Neoplasma; 2014; 61(1):99-109. PubMed ID: 24195516
[TBL] [Abstract][Full Text] [Related]
18. Functional characterization of three naturally occurring single nucleotide polymorphisms in the CES2 gene encoding carboxylesterase 2 (HCE-2).
Kubo T; Kim SR; Sai K; Saito Y; Nakajima T; Matsumoto K; Saito H; Shirao K; Yamamoto N; Minami H; Ohtsu A; Yoshida T; Saijo N; Ohno Y; Ozawa S; Sawada J
Drug Metab Dispos; 2005 Oct; 33(10):1482-7. PubMed ID: 16033949
[TBL] [Abstract][Full Text] [Related]
19. Regulation of carboxylesterase-2 expression by p53 family proteins and enhanced anti-cancer activities among 5-fluorouracil, irinotecan and doxazolidine prodrug.
Xiao D; Yang D; Guo L; Lu W; Charpentier M; Yan B
Br J Pharmacol; 2013 Apr; 168(8):1989-99. PubMed ID: 23373735
[TBL] [Abstract][Full Text] [Related]
20. The pharmacogenetics of carboxylesterases: CES1 and CES2 genetic variants and their clinical effect.
Merali Z; Ross S; Paré G
Drug Metabol Drug Interact; 2014; 29(3):143-51. PubMed ID: 24988246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
